Zemaira Convention Promotions Omit Risk Information, CBER Letter Says
Executive Summary
ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention
You may also be interested in...
Coreg Convention Promo Misleads On Mortality Benefit – FDA Warning Letter
A promotional exhibit for GlaxoSmithKline's Coreg (carvedilol) exaggerates the beta blocker's mortality benefit, an FDA ad division warning letter states
Coreg Convention Promo Misleads On Mortality Benefit – FDA Warning Letter
A promotional exhibit for GlaxoSmithKline's Coreg (carvedilol) exaggerates the beta blocker's mortality benefit, an FDA ad division warning letter states
Aventis Divests Behring: CSL Enters Factor VIII Market In $925 Mil. Deal
CSL will enter the U.S. Factor VIII market though its acquisition of Aventis Behring in a deal worth up to $925 mil